Clinical trial
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally…
NCT00028990 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00028990 |
|---|---|
| Title | Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer |
| Official title | A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH North Central Cancer Treatment Group NCIC Clinical Trials Group NSABP Foundation Inc |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, Paclitaxel |
| Enrollment | 722 |
| Start date | Jan 29, 2002 |
| Primary completion | Nov 1, 2006 |
| Completion | May 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 15, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: